Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 4
2005 7
2006 4
2007 5
2008 5
2009 2
2010 3
2011 3
2012 4
2013 2
2014 4
2015 5
2016 2
2017 4
2018 3
2019 2
2020 8
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Tubulin-targeting agents.
Hait WN, Rubin E, Goodin S. Hait WN, et al. Among authors: goodin s. Cancer Chemother Biol Response Modif. 2005;22:35-59. doi: 10.1016/s0921-4410(04)22003-8. Cancer Chemother Biol Response Modif. 2005. PMID: 16110607 Review. No abstract available.
Tubulin-targeting agents.
Hait WN, Rubin E, Goodin S. Hait WN, et al. Among authors: goodin s. Cancer Chemother Biol Response Modif. 2003;21:41-67. doi: 10.1016/s0921-4410(03)21003-6. Cancer Chemother Biol Response Modif. 2003. PMID: 15338740 Review. No abstract available.
Novel cytotoxic agents: epothilones.
Goodin S. Goodin S. Am J Health Syst Pharm. 2008 May 15;65(10 Suppl 3):S10-5. doi: 10.2146/ajhp080089. Am J Health Syst Pharm. 2008. PMID: 18463327 Review.
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
Spencer KR, Portal DE, Aisner J, Stein MN, Malhotra J, Shih W, Chan N, Silk AW, Ganesan S, Goodin S, Gounder M, Lin H, Li J, Cerchio R, Marinaro C, Chen S, Mehnert JM. Spencer KR, et al. Among authors: goodin s. Oncotarget. 2023 Apr 10;14:302-315. doi: 10.18632/oncotarget.28403. Oncotarget. 2023. PMID: 37036756 Free PMC article. Clinical Trial.
Cancer-treatment-induced bone loss, part 2.
Michaud LB, Goodin S. Michaud LB, et al. Among authors: goodin s. Am J Health Syst Pharm. 2006 Mar 15;63(6):534-46. doi: 10.2146/ajhp050045.p2. Am J Health Syst Pharm. 2006. PMID: 16522890 Review.
Cancer-treatment-induced bone loss, part 1.
Michaud LB, Goodin S. Michaud LB, et al. Among authors: goodin s. Am J Health Syst Pharm. 2006 Mar 1;63(5):419-30. doi: 10.2146/ajhp050045.p1. Am J Health Syst Pharm. 2006. PMID: 16484516 Review.
Abiraterone in prostate cancer: a new angle to an old problem.
Stein MN, Goodin S, Dipaola RS. Stein MN, et al. Among authors: goodin s. Clin Cancer Res. 2012 Apr 1;18(7):1848-54. doi: 10.1158/1078-0432.CCR-11-1805. Epub 2012 Mar 26. Clin Cancer Res. 2012. PMID: 22451619 Free PMC article. Review.
71 results